reata pharmaceuticals, inc. (nasdaq:reta) is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. reata’s two most advanced clinical candidates, bardoxolone methyl and omaveloxolone, target the important transcription factor nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.
Company profile
Ticker
RETA
Exchange
Website
CEO
J. Warren Huff
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Reata Pharmaceuticals Holdings, LLC • Reata Pharmaceuticals Global, Inc. • Reata Swiss International GmbH • Reata UK Ltd • Reata Australia Pty Limited • Reata Ireland Limited • Reata France SAS • Reata Italy S.r.l. ...
RETA stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
6 Oct 23
8-K
Termination of a Material Definitive Agreement
26 Sep 23
POSASR
Automatic shelf registration (post-effective amendment)
26 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Sep 23
Transcripts
RETA
Earnings call transcript
2023 Q1
10 May 23
RETA
Earnings call transcript
2022 Q3
8 Nov 22
RETA
Earnings call transcript
2022 Q2
8 Aug 22
RETA
Earnings call transcript
2022 Q1
10 May 22
RETA
Earnings call transcript
2021 Q4
28 Feb 22
RETA
Earnings call transcript
2021 Q3
8 Nov 21
RETA
Earnings call transcript
2021 Q2
10 Aug 21
RETA
Earnings call transcript
2021 Q1
9 May 21
RETA
Earnings call transcript
2020 Q4
1 Mar 21
RETA
Earnings call transcript
2020 Q3
9 Nov 20
Latest ownership filings
Financial summary
Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 48.84 mm | 48.84 mm | 48.84 mm | 48.84 mm | 48.84 mm | 48.84 mm |
Cash burn (monthly) | 12.03 mm | 8.19 mm | (no burn) | 7.31 mm | 23.31 mm | 20.69 mm |
Cash used (since last report) | 118.58 mm | 80.74 mm | n/a | 72.00 mm | 229.71 mm | 203.94 mm |
Cash remaining | -69.73 mm | -31.89 mm | n/a | -23.16 mm | -180.87 mm | -155.10 mm |
Runway (months of cash) | -5.8 | -3.9 | n/a | -3.2 | -7.8 | -7.5 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 214 |
Opened positions | 44 |
Closed positions | 35 |
Increased positions | 71 |
Reduced positions | 60 |
13F shares | Current |
---|---|
Total value | 3.13 tn |
Total shares | 34.05 mm |
Total puts | 629.78 k |
Total calls | 688.90 k |
Total put/call ratio | 0.9 |
Largest owners | Shares | Value |
---|---|---|
CPMG | 2.90 mm | $295.37 bn |
Vanguard | 2.82 mm | $287.68 bn |
Rose William | 2.76 mm | $389.19 mm |
BLK Blackrock | 2.54 mm | $258.85 bn |
Adage Capital Partners GP, L.L.C. | 1.77 mm | $180.07 bn |
DB Deutsche Bank AG - Registered Shares | 1.49 mm | $151.56 bn |
Wellington Management | 1.47 mm | $150.09 bn |
First Light Asset Management | 1.43 mm | $146.03 bn |
Boxer Capital | 1.43 mm | $147.30 bn |
JHG Janus Henderson | 1.05 mm | $107.17 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
26 Sep 23 | Bir Dawn Carter | Class A common stock | Sale back to company | Dispose D | No | No | 0 | 33,805 | 0.00 | 0 |
26 Sep 23 | Bir Dawn Carter | Employee Stock Option Class B common stock | Sale back to company | Dispose D | No | No | 207.2 | 24,000 | 4.97 mm | 0 |
26 Sep 23 | Bir Dawn Carter | Employee Stock Option Class B common stock | Sale back to company | Dispose D | No | No | 55.73 | 17,250 | 961.34 k | 0 |
26 Sep 23 | Bir Dawn Carter | Employee Stock Option Class B common stock | Sale back to company | Dispose D | No | No | 55.73 | 17,250 | 961.34 k | 0 |
26 Sep 23 | Bir Dawn Carter | Employee Stock Option Class B common stock | Sale back to company | Dispose D | No | No | 55.73 | 34,500 | 1.92 mm | 0 |
26 Sep 23 | Bir Dawn Carter | Employee Stock Option Class B common stock | Sale back to company | Dispose D | No | No | 24.75 | 71,300 | 1.76 mm | 0 |
26 Sep 23 | Bir Dawn Carter | Employee Stock Option Class A common stock | Sale back to company | Dispose D | No | No | 36.71 | 63,650 | 2.34 mm | 0 |
26 Sep 23 | Bir Dawn Carter | Employee Stock Option Class A common stock | Sale back to company | Dispose D | No | No | 27.32 | 70,000 | 1.91 mm | 0 |
26 Sep 23 | Bir Dawn Carter | Employee Stock Option Class A common stock | Sale back to company | Dispose D | No | No | 121.29 | 16,500 | 2.00 mm | 0 |
26 Sep 23 | Rajiv Patni | Class A common stock | Sale back to company | Dispose D | No | No | 0 | 45,000 | 0.00 | 0 |